Originally Published MX
September/October 2003
Government & Legal Affairs
Disclosure Management|
Return
to article: |
To avoid premature, overoptimistic, or other problematic disclosure of potentially false or misleading information emerging from clinical studies, medtech company executives should:
• Restrict access to sensitive information to only those who need to know.
• Make public announcements only when products are in late stages of clinical development.
• Create a written corporate disclosure policy.
• Train employees to observe the policy.
• Consult FDA whenever in doubt.
Copyright ©2003 MX
